Amylyx Pharmaceuticals, Inc. - Common Stock

Share · US03237H1014 · AMLX (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Amylyx Pharmaceuticals, Inc. - Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

20.04.2026 23:56

Current Prices from Amylyx Pharmaceuticals, Inc. - Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	AMLX	USD	20.04.2026 23:56	17,56 USD	-0,96 USD -5,16 %
IEX	AMLX	USD	20.04.2026 19:59	17,58 USD	-0,94 USD -5,05 %

Share Float & Liquidity

Free Float 66,48 %

Shares Float 55,26 M

Shares Outstanding 83,13 M

Company Profile for Amylyx Pharmaceuticals, Inc. - Common Stock Share

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.